Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Cancer Vaccines01:30

Cancer Vaccines

926
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
926
MicroRNAs01:22

MicroRNAs

3.7K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.7K
MicroRNAs01:22

MicroRNAs

23.8K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.8K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

911
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
911
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

6.3K
Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rhabdomyomas of the Mitral Valve: Case Series and Conservative Management Approach.

Pediatric cardiology·2026
Same author

Diagnostic Translational Considerations for Global Health Settings: Portable Detection of Human Papillomavirus for Cervical Cancer Screening in India.

JCO global oncology·2025
Same author

Mechanistic basis for a novel dual-function Gag-Pol dimerizer potentiating CARD8 inflammasome activation and clearance of HIV-infected cells.

NPJ drug discovery·2025
Same author

Serum profiling of the antibody response to HPV in women with or without abnormal cervical cytology undergoing cervical cancer screening.

Frontiers in immunology·2025
Same author

A virtual screening strategy to repurpose antifolate compounds as W.bancrofti DHFR inhibitors.

Bioorganic & medicinal chemistry letters·2025
Same author

Rapid on-chip nucleic acid extraction for point-of-care salivary diagnostics.

Analytical methods : advancing methods and applications·2025

Related Experiment Video

Updated: Jan 7, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.1K

Engineering Anti-Tumor Immunity: An Immunological Framework for mRNA Cancer Vaccines.

Olivia Roy1,2, Karen S Anderson2,3

  • 1School of Molecular Sciences, Arizona State University, Tempe, AZ 85287, USA.

Vaccines
|December 24, 2025
PubMed
Summary

Messenger RNA (mRNA) vaccines are revolutionizing cancer immunotherapy by inducing potent, tumor-specific immune responses. Optimizing mRNA vaccine design through engineering and antigen selection is key for durable clinical benefit against cancer.

Keywords:
antigen presentationcancer immunotherapyepitope engineeringlipid nanoparticlesmRNA vaccinesmulti-epitope vaccine designprecision oncologytumor microenvironment

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.2K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.8K

Related Experiment Videos

Last Updated: Jan 7, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.1K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.2K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.8K

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Background:

  • Messenger RNA (mRNA) vaccines represent a significant advancement in cancer immunotherapy, offering rapid and clinically viable strategies.
  • These vaccines are designed to elicit potent, tumor-specific immune responses, redefining the therapeutic landscape.

Purpose of the Study:

  • To review current advances in mRNA engineering and antigen design for cancer vaccines.
  • To establish an integrated immunological framework for developing effective mRNA cancer vaccines.
  • To explore molecular design principles that enhance immunogenicity and therapeutic efficacy.

Main Methods:

  • Examination of mRNA engineering techniques, including nucleoside modifications, codon optimization, and untranslated regions.
  • Analysis of antigen design strategies and epitope selection for optimal immune targeting.
  • Review of delivery systems and immune monitoring protocols for mRNA cancer vaccines.

Main Results:

  • Effective cancer vaccines require more than antigen expression; precise epitope selection, optimized delivery, and immune monitoring are crucial.
  • The focus is shifting towards molecular design principles that enhance the magnitude, polyfunctionality, and longevity of immune responses.
  • Rational molecular engineering of vaccine components significantly influences immunogenicity and therapeutic outcomes.

Conclusions:

  • An integrated immunological framework is essential for advancing mRNA cancer vaccine development.
  • Overcoming tumor-induced immune suppression requires a focus on biochemistry and molecular design.
  • Future strategies will likely involve combining mRNA vaccination with immune checkpoint inhibitors and adoptive cell therapies for enhanced efficacy.